No, Pyxis Oncology does not pay dividends. As a clinical-stage biotechnology enterprise operating in a capital-intensive sector, the company directs all of its financial resources, capital raises, and partnership funds entirely toward research and development, preclinical testing, and advancing its oncology clinical pipelines. Investors seeking immediate regular income through dividend payouts will not find them with clinical-stage biotech equities of this nature.